Adi J Klil-Drori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2092612/publications.pdf

Version: 2024-02-01

| | | 1684188 | 1058476 | |
|----------|----------------|--------------|----------------|--|
| 15 | 252 | 5 | 14 | |
| papers | citations | h-index | g-index | |
| | | | | |
| | | | | |
| | | | | |
| 15 | 15 | 15 | 690 | |
| all docs | docs citations | times ranked | citing authors | |
| | | | | |

| # | Article | IF | Citations |
|----|---|-----------|----------------------------|
| 1 | Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?. Nature Reviews Clinical Oncology, 2017, 14, 85-99. | 27.6 | 163 |
| 2 | Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism. European Urology, 2016, 70, 56-61. | 1.9 | 38 |
| 3 | Temporal trends in outpatient management of incident pulmonary embolism and associated mortality. Thrombosis Research, 2018, 161, 111-116. | 1.7 | 20 |
| 4 | Early switch to secondâ€line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response. American Journal of Hematology, 2017, 92, E602-E604. | 4.1 | 5 |
| 5 | Serum organochlorines and non-Hodgkin lymphoma: A case-control study in Israeli Jews and Palestinians. Chemosphere, 2018, 213, 395-402. | 8.2 | 5 |
| 6 | External Validation of ASPECT (Algorithm for Suspected Pulmonary Embolism Confirmation and) Tj ETQq0 0 0 rg | BT/Qverlo | ck ₄ 10 Tf 50 5 |
| 7 | Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study. Haematologica, 2019, 104, e293-e295. | 3.5 | 4 |
| 8 | The Role of Selection in the Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation. JAMA Internal Medicine, 2015, 175, 1243. | 5.1 | 3 |
| 9 | Statins in Multiple Myeloma: Survival Benefit or Immortal Time Bias?. Journal of Clinical Oncology, 2017, 35, 1377-1378. | 1.6 | 2 |
| 10 | Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia. Cancer, 2019, 125, 618-625. | 4.1 | 2 |
| 11 | The Risk of Major Bleeding with Low-Molecular-Weight-Heparins for Venous Thromboembolism in Dialysis Patients: The Q-VTE Study. Blood, 2016, 128, 89-89. | 1.4 | 2 |
| 12 | Prolactin-Elevating Antipsychotics and the Risk of Endometrial Cancer. Journal of Clinical Psychiatry, 2017, 78, 714-719. | 2.2 | 2 |
| 13 | Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study. Drug Safety, 2019, 42, 1005-1011. | 3.2 | 1 |
| 14 | Comparative Risk of Acute Kidney Injury with Oral Anticoagulant Use Among Patients with Nonvalvular Atrial Fibrillation. Blood, 2017, 130, 700-700. | 1.4 | 1 |
| 15 | Reply to Mieke Van Hemelrijck, Hans Garmo, Jan Adolfsson, and PäStattin's Letter to the Editor re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol 2016;70:56–61. European Urology, 2017. 71. e63. | 1.9 | 0 |